KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Accumulated Expenses: 2011-2025

Historic Accumulated Expenses for TherapeuticsMD (TXMD) over the last 8 years, with Sep 2025 value amounting to $2.0 million.

  • TherapeuticsMD's Accumulated Expenses was N/A to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2024, which is 32.11% down from last year.
  • Per TherapeuticsMD's latest filing, its Accumulated Expenses stood at $2.0 million for Q3 2025, which was up 26.73% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Accumulated Expenses ranged from a high of $51.7 million in Q3 2021 and a low of $1.6 million during Q2 2025.
  • Its 3-year average for Accumulated Expenses is $2.1 million, with a median of $2.0 million in 2025.
  • In the last 5 years, TherapeuticsMD's Accumulated Expenses soared by 1,079.31% in 2021 and then slumped by 32.11% in 2024.
  • TherapeuticsMD's Accumulated Expenses (Quarterly) stood at $44.3 million in 2021, then reached $3.1 million in 2023, then crashed by 32.11% to $2.1 million in 2024, then reached $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $1.6 million for Q2 2025, and $1.8 million during Q1 2025.